ZAI LAB LIMITED Treasury Stock, Common, Value
ZAI LAB LIMITED (ZLAB) had Treasury Stock, Common, Value of $33.52 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:TreasuryStockCommonValue · last filed 2026-08-06
- 2026-06-30: Treasury Stock, Common, Value $33.52M.
- 2026-03-31: Treasury Stock, Common, Value $31.32M.
- 2025-12-31: Treasury Stock, Common, Value $29.05M.
- 2025-09-30: Treasury Stock, Common, Value $29.05M.
| Period end | Treasury Stock, Common, Value |
|---|---|
| 2026-06-30 | $33.52M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $31.32M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $29.05M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $29.05M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $20.86M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $20.84M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $20.84M 10-K · filed 2026-02-26 |
| 2024-09-30 | $20.84M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $20.84M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $20.84M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $20.84M 10-K · filed 2025-02-27 |
| 2023-09-30 | $20.79M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $20.53M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $16.99M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $11.86M 10-K · filed 2024-02-27 |
| 2022-09-30 | $11.46M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $11.13M 10-Q · filed 2022-08-09 |
| 2021-12-31 | $4.28M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |